

ARTICLE OPEN



Distinct airway epithelial immune responses after infection with SARS-CoV-2 compared to H1N1

Helen Stölting¹, Laury Baillon², Rebecca Frise², Katie Bonner^{1,3,4}, Richard J. Hewitt^{1,4}, Philip L. Molyneaux^{1,4}, Mindy L. Gore¹, Breathing Together Consortium*, Wendy S. Barclay², Sejal Saglani^{1,16 \boxtimes} and Clare M. Lloyd \bigcirc 1,16 \boxtimes

© The Author(s) 2022

Children are less likely than adults to suffer severe symptoms when infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while influenza A H1N1 severity is comparable across ages except for the very young or elderly. Airway epithelial cells play a vital role in the early defence against viruses via their barrier and immune functions. We investigated viral replication and immune responses in SARS-CoV-2-infected bronchial epithelial cells from healthy paediatric (n = 6; 2.5–5.6 years old) and adult (n = 4; 47–63 years old) subjects and compared cellular responses following infection with SARS-CoV-2 or Influenza A H1N1. While infection with either virus triggered robust transcriptional interferon responses, including induction of type I (*IFNB1*) and type III (*IFNL1*) interferons, markedly lower levels of interferons and inflammatory proteins (IL-6, IL-8) were released following SARS-CoV-2 compared to H1N1 infection. Only H1N1 infection caused disruption of the epithelial layer. Interestingly, H1N1 infection resulted in sustained upregulation of SARS-CoV-2 entry factors *FURIN* and *NRP1*. We did not find any differences in the epithelial response to SARS-CoV-2 infection between paediatric and adult cells. Overall, SARS-CoV-2 had diminished potential to replicate, affect morphology and evoke immune responses in bronchial epithelial cells compared to H1N1.

Mucosal Immunology (2022) 15:952-963; https://doi.org/10.1038/s41385-022-00545-4

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 19 (COVID-19), a global pandemic that originated in Wuhan, China, at the end of 2019 and has resulted in over 6 million deaths to date (according to WHO, as of March 2022). While H1N1pdm09, the influenza A virus responsible for the 2009 pandemic, can cause severe disease in both children and adults¹, detrimental outcomes of COVID-19 are more prominent in adults, with roughly 20% having developed severe or critical disease during the first wave of COVID-19^{2,3}. In contrast, SARS-CoV-2-infected children typically remain asymptomatic or experience mild to moderate symptoms, and severe disease or fatality are rare $^{4-6}$. Some studies propose that, in addition to decreased severity, susceptibility to infection is also reduced in children compared to adults^{7–9}, but the potential mechanisms underlying these discrepancies remain poorly understood. Entry of SARS-CoV-2 into host cells is dependent on angiotensin converting enzyme 2 (ACE2), which acts as a receptor for SARS-CoV-2 Spike protein, and the protease transmembrane protease serine 2 (TMPRSS2)¹⁰. In addition, other host factors, such as cathepsin L, furin proteases and neuropilins, have been ascribed important roles in the pre-activation and entry of SARS-CoV-2^{11–15}. Decreased expression of SARS-CoV-2 entry-related genes in children compared to adults has been described 16,17 offering a potential explanation for differing susceptibility to infection, but reports are conflicting and differences in the expression of these host factors between children and adults have not been confirmed in other studies $^{18-21}$.

The airway epithelium acts as an important first line of defence against respiratory viruses, not only by providing a physical barrier between the external environment and the internal milieu, but also via the release of antiviral and pro-inflammatory mediators²² Airway epithelial cells express a range of pattern recognition receptors (PRRs), such as the endosomal Toll-like receptors (TLRs) TLR3, TLR7, TLR8 and TLR9 and the cytoplasmic receptors retinoic acid-inducible gene I (RIG-I) and melanoma differentiationassociated gene 5 (MDA5), which allow them to sense viruses and initiate the antiviral interferon response. Upon viral recognition, airway epithelial cells constitute an early source of type I and III interferons (IFNs), which act to rapidly establish an antiviral state via the induction of hundreds of interferon-stimulated genes (ISGs). In particular, type I IFNs are crucial in the successful defence against respiratory viruses such as influenza virus²³, and mounting evidence suggests that the early type I IFN response is also central to the response to SARS-CoV-2²⁴-

In addition to their role in initiating antiviral responses, both nasal and bronchial epithelial cells are also considered primary portals of entry for SARS-CoV-2²⁷, not least due to their expression of both ACE2 and TMPRSS2²⁸. Air–liquid interface (ALI) cultures of primary airway epithelial cells are an ideal model for the study of viral infections, as they form a polarised, highly differentiated mucociliary layer representative of the

¹National Heart and Lung Institute, Imperial College London, London, UK. ²Department of Infectious Disease, Imperial College London, London, UK. ³Chelsea and Westminster Hospital Foundation Trust, London, UK. ⁴Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK. ¹⁷These authors contributed equally: Sejal Saglani, Clare M. Lloyd. *A list of authors and their affiliations appears at the end of the paper. [™]email: s.saglani@imperial.ac.uk; c.lloyd@imperial.ac.uk

Received: 26 November 2021 Revised: 30 May 2022 Accepted: 16 June 2022

Published online: 15 July 2022

in vivo airway wall²⁹ and retain donor disease characteristics such as age or disease status^{30–32}. Accordingly, ALI cultures have been widely used to investigate responses to SARS-CoV-2 infection 15,33-36. However, a detailed characterisation of SARS-CoV-2 infection in paediatric airway epithelial cells compared to adult cells is lacking. While some groups have also used infection with H1N1 as a comparator for SARS-CoV-2³⁶⁻³⁸, an approach that has revealed differences in the interferon induction between the two viruses, these studies have been restricted to analysis of gene expression and early time points. We hypothesised that the disparate severity of COVID-19 in children and adults could be explained by intrinsic differences in airway epithelial cells from these groups and that SARS-CoV-2 and H1N1 would evoke distinct responses in these cells We infected ALI cultures of primary bronchial epithelial cells from healthy children (n = 6) and adults (n = 4) with an early-lineage clinical isolate of SARS-CoV-2 (England/IC19/2020) or the pandemic strain of H1N1 (A/England/195/2009) to directly compare susceptibility to infection and epithelial antiviral immune responses according to age and virus. We monitored productive infection using plaque assays and immunofluorescence staining for SARS-CoV-2 nucleocapsid protein up until 9 days post-infection (dpi). Interferon and inflammatory responses were assessed at mRNA and protein level, and we measured gene expression levels of SARS-CoV-2 entry-related factors and receptors involved in SARS-CoV-2 recognition both at baseline and in response to viral infection.

RESULTS

Bronchial epithelial cells from paediatric and adult donors displayed comparable cellular composition and SARS-CoV-2 entry factor expression

We aimed to study whether differences in COVID-19 susceptibility and severity between children and adults might be explained by intrinsically disparate epithelial cell responses to infection. To this end, we collected bronchial epithelial cells from six healthy children (median age 4.6 years) and four healthy adults (median age 52.5 years; Table 1). There were no differences between nasal and bronchial epithelial cells from paediatric donors with respect to cell morphology, replication of SARS-CoV-2 or interferon response to infection (Supplementary Fig. 1A–C), and therefore bronchial epithelial cells were used as a model of the airway epithelium throughout this study.

Table 1.	Donor	demographics
----------	-------	--------------

	Paediatric (n = 6)	Adult (n = 4)
Median age (range)	4.6 (2.5–5.6)	52.5 (47–63)
Male/female	3/3	2/2
Ethnicity (%)		
Asian	1 (17%)	2 (50%)
White Caucasian	4 (67%)	2 (50%)
Mixed Black/White Caucasian	1 (17%)	-
Atopy status (%)		
Atopic	3 (50%)	-
Non-Atopic	3 (50%)	-
Unknown	-	4 (100%)
Smoking status (%)		
Current smoker		0 (–)
Ex-smoker	n/a	2 (50%)
Never smoker		2 (50%)

When cultured at air-liquid interface and fully differentiated, epithelial cells from both age groups showed similar morphology, characterised by the presence of basal cells (KRT5⁺), goblet cells (MUC5AC⁺) and ciliated cells (acetylated alpha-tubulin⁺, Fig. 1a), and no differences in the expression of genes related to epithelial cell subsets or tight junction formation (TJP1) were observed between the groups (Fig. 1b). Epithelial height varied slightly between donors of both groups (Fig. 1c). We also examined the expression levels of ACE2 and TMPRSS2, two cell surface proteins required for SARS-CoV-2 entry, as well as further SARS-CoV-2 entry-related genes (CTSL, FURIN, NRP1 and NRP2), and found all of them to be expressed at comparable levels between groups (Fig. 1d), suggesting similar susceptibility to SARS-CoV-2 entry. ACE2 expression was further confirmed at the protein level by immunofluorescence staining, where it was detected across the entire cell layer (Fig. 1e), indicating its expression by ciliated cells, basal cells and at least a proportion of goblet cells (Supplementary Fig. 2). Lastly, we measured expression levels of DDX58 (encoding RIG-I) and IFIH1 (encoding MDA5), two PRRs proven (MDA5) or speculated (RIG-I) to be important in the recognition of SARS-CoV-2^{20,35,39}. While both genes were detectable in uninfected cells, there were no differences in expression levels between paediatric and adult cells (Fig. 1f). Overall, our analysis did not reveal any intrinsic differences between paediatric and adult cells that would be expected to result in disparate susceptibility to SARS-CoV-2 entry or capacity for viral recognition.

Age did not distinguish epithelial susceptibility and immune responses to SARS-CoV-2, which were minimal compared to H1N1

To compare viral replication between age groups and viruses, as well as to study the resultant cellular immune responses, bronchial epithelial cells were infected with SARS-CoV-2 (SARS-CoV-2/ England/IC19/2020; MOI 0.01) or Influenza A H1N1 virus (A/ England/195/2009; MOI 0.001) (Supplementary Fig. 1D). To investigate which epithelial subtypes were infected by SARS-CoV-2, we performed immunofluorescence staining for SARS-CoV-2 nucleocapsid protein (NP) in cell layers at 3 or 5 dpi (Fig. 2a, b). The majority of SARS-CoV-2 NP signal did not co-localise with either KRT5 or MUC5AC signal. These data, coupled with the apical location of the SARS-CoV-2 NP staining suggest that ciliated, not basal or goblet cells, were the primary site of SARS-CoV-2 infection. We also noticed a clear increase in the number of infected cells between 3 and 5 dpi (Fig. 2a, b), indicative of continued replication of the virus, which was further confirmed by performing plaque assays on apical washes. Release of infectious SARS-CoV-2 particles from infected cells peaked at around 3–5 dpi and remained detectable throughout the duration of the experiment (9 dpi; Fig. 2c). In line with comparable expression of SARS-CoV-2 entry and pattern recognition receptors, we did not observe any differences between paediatric and adult cells regarding viral replication at any stage during the infection (Fig. 2c). Notably, levels of infectious particles released from H1N1infected cells were several log-fold higher than from SARS-CoV-2infected cells, especially at the earliest time point (1 dpi), indicating a better ability of H1N1 to replicate in bronchial epithelial cell cultures compared to SARS-CoV-2, at least for these donors and virus strains.

In addition to viral titres, we also compared immune responses to SARS-CoV-2 infection between paediatric and adult cells (Figs. 3–5). Principal component analysis (PCA) of SARS-CoV-2-infected cells based on 121 variables measured in this study, comprising viral titres, gene expression levels and concentrations of secreted proteins at five different time points, showed a complete overlap between paediatric and adult donors (Fig. 2d), implying that in our subjects, age is unlikely to be a driver of heterogeneity between donors. Our data may suggest that paediatric and adult airway epithelial cells were indistinguishable in their response to infection




Fig. 1 Bronchial epithelial cells from paediatric and adult donors displayed comparable cellular composition and SARS-CoV-2 entry factor expression. a Representative images of H&E or immunofluorescence staining of uninfected bronchial epithelial cells from paediatric and adult donors. Immunofluorescence: Ciliated cells (acetylated alpha tubulin; magenta), basal cells (KRT5; cyan) and goblet cells (MUC5AC; yellow). Length of scale bar: 50 μm. b Gene expression analysis by qPCR from uninfected bronchial epithelial cells. c Epithelial height measured in cross-section of fixed bronchial epithelial cells from paediatric or adult donors. d Gene expression analysis by qPCR from uninfected bronchial epithelial cells. e Representative images of staining for KRT5 (cyan), ACE2 (magenta) and MUC5AC (yellow) in uninfected bronchial cells from paediatric and adult donors. Size of scale bar: 50 μm. f Gene expression analysis by qPCR from uninfected bronchial epithelial cells.

with SARS-CoV-2 within our experimental setup. However, the inability to detect differences between age groups may also be explained by the limited sample size. We also employed PCA to compare all experimental conditions across the gene expression and protein data collected in this study (Fig. 2e). This analysis revealed stark differences between SARS-CoV-2-infected cells, which partly overlapped with uninfected cells, and H1N1-infected cells, which displayed a clear separation from the other conditions, suggesting a much greater ability of H1N1 to evoke epithelial cell responses compared to SARS-CoV-2.

Infection of epithelial cells with SARS-CoV-2 did not alter gross cellular morphology

Given the considerable divergence between H1N1- and SARS-CoV2-infected cells brought to light by the principal component analysis, we sought to characterise the disparate effects of the two viruses on bronchial epithelial cells in more detail. We used a combination of traditional haematoxylin and eosin staining and

gene expression analysis of cell layers to assess the consequences of infection on overall morphology and epithelial integrity. While infection with H1N1 severely affected the structure and height of the cell layer (Fig. 3a) and further led to reduced expression of ciliated, basal and goblet cell genes (Fig. 3b), SARS-CoV-2 did not alter gross cell morphology and even resulted in increased levels of TJP1. We also measured the expression of the epidermal growth factor receptor (*EGFR*), a receptor thought to be important for airway epithelial repair⁴⁰, as well as its seven ligands: amphiregulin (AREG), betacellulin (BTC), epidermal growth factor (EGF; not shown), epigen (EPGN; not detected), epiregulin (EREG), heparinbinding EGF-like (HBEGF) and transforming growth factor-alpha (TGFA). While infection with both viruses led to significant increases in ligand expression, the effects of H1N1 infection were wider-ranging and of greater magnitude (Fig. 3c). Taken together, these data suggest that, in comparison to infection with H1N1, SARS-CoV-2 only caused minimal damage and subsequent repair of the epithelium.




Fig. 2 Age did not distinguish epithelial susceptibility and immune responses to SARS-CoV-2, which were minimal compared to H1N1.

a, b Representative images of immunofluorescence staining for SARS-CoV-2 nucleocapsid protein (NP) (magenta), MUC5AC (yellow) and KRT5 (cyan) in SARS-CoV-2-infected cells at 3 (A) or 5 (B) days post-infection (dpi). Size of scale bar: 50 μm. c Viral titres in apical wash of epithelial cells infected with SARS-CoV-2 or H1N1 as determined by plaque assays. Line graph in (A) shows median + confidence interval. d Principal component analysis of SARS-CoV-2-infected cells based on 121 variables (viral titres, expression of 28 genes and concentration of 2 proteins across up to five time points). Each data point represents one donor. e Principal component analysis of epithelial cells based on 98 variables (expression of 28 genes and concentration of 2 proteins across up to five time points). Each data point represents one treatment of one donor.




Fig. 3 Infection of epithelial cells with SARS-CoV-2 did not alter gross cellular morphology. a Representative images of H&E staining of paediatric or adult bronchial epithelial cells infected with SARS-CoV-2 (CoV-2), H1N1 or treated with medium (ctrl) at 3 and 5 days post-infection (dpi). b, c Gene expression analysis by qPCR of infected bronchial epithelial cells. Coloured asterisks indicate statistically significant changes from uninfected conditions. Black bar and asterisk indicate statistically significant differences between paediatric and adult cells. Statistics: Mann–Whitney test. *p < 0.05; **p < 0.01.

Infection with SARS-CoV-2 elicited antiviral and proinflammatory transcriptional programmes, which were significantly weaker than with H1N1 infection

We next considered the epithelial immune response. Infection with SARS-CoV-2 strongly induced the expression of type I (IFNB1) and type III (IFNL1) IFNs as well as several ISGs, although peak expression levels resulting from SARS-CoV-2 infection were lower than after H1N1 infection (Fig. 4a, b, Fig S3A). Infection with either virus also resulted in an induction of the pro-inflammatory genes CXCL8 (encoding IL-8), IL6 and TNF, albeit to a lesser extent in SARS-CoV-2-infected cells (Fig. 4c). Importantly, however, expression levels of interferon signalling genes as well as pro-inflammatory genes strongly correlated with infectious titres of

both viruses in apical washes (Fig. 4d, Supplementary Fig. 3A, B), suggesting that the milder inflammatory response observed in SARS-CoV-2-infected cells may result from lower viral replication in these cells. Apart from slightly elevated expression of *IFNB1* and *TNF* in H1N1-infected adult compared to paediatric cells at 9 dpi (p = 0.016), there were no differences between the age groups.

Protein production by epithelial cells in response to SARS-CoV-2 infection was minimal compared to H1N1

In addition to the transcriptional response, we also measured proteins secreted by epithelial cells infected with either SARS-CoV-2 or H1N1. As expected, H1N1 infection resulted in release of IFN- β , IFN- λ , IL-6 and IL-8 into the basal media (Fig. 5a, b), of which IL-8




Fig. 4 Infection with SARS-CoV-2 elicited antiviral and pro-inflammatory transcriptional programmes, which were significantly weaker than with H1N1 infection. a–c Gene expression analysis by qPCR of infected bronchial epithelial cells. Data are shown as median + confidence interval. d Spearman correlation between viral titres and gene expression of *IFNB1* or *TNF* of paediatric and adult cells infected with SARS-CoV-2 or H1N1. Correlation coefficients and p values are shown for each treatment individually (purple, SARS-CoV-2; teal, H1N1).

alone was also present in media from uninfected cells (Supplementary Fig. 4A). In contrast, only IFN- λ and IL-8 were detected in media from SARS-CoV-2-infected cells, at levels approximately 5to 40-fold lower than after H1N1 infection (Fig. 5a, b). To address whether elevated interferon levels in the basal media of H1N1infected cells might be secondary to increased leakage of apically released protein as a result of damage to the epithelial layer, we also measured levels of IFN-β and IFN-λ in apical washes of infected cells (Supplementary Fig. 4B). Apical release of both interferons in response to SARS-CoV-2, while detectable, fell short of levels measured after H1N1, indicating an overall diminished ability of SARS-CoV-2 to elicit antiviral or pro-inflammatory protein production in bronchial epithelial cells from healthy individuals. In line with this, basolateral protein release after H1N1 infection strongly correlated with viral titres, whereas we found no or only weak correlation between titres and measured protein levels from SARS-CoV-2-infected cells (Fig. 5c)This finding was further supported when levels of 105 cytokines and chemokines were measured in pooled basal media from infected paediatric (n = 4) or adult (n = 4) epithelial cells using a membrane-based protein array, where infection with SARS-CoV-2 had little effect on the

proteins detected, whereas H1N1 induced a wide range of analytes (Supplementary Fig. 4B). Overall, these data confirm that, when compared to H1N1, SARS-CoV-2 had a diminished potential to affect epithelial morphology or induce interferon and proinflammatory responses at both mRNA and protein level, which may at least in part result from its relatively reduced replication in healthy bronchial epithelial cells.

Infection of bronchial epithelial cells with H1N1 resulted in prolonged upregulation of SARS-CoV-2 entry-related genes independent of viral titres

Finally, we aimed to investigate whether viral infection can alter the expression of genes involved in SARS-CoV-2 cell entry and could thus potentially affect susceptibility to subsequent infections. As we did not observe any differences between paediatric and adult cells, both groups were pooled for this analysis. While the expression of entry-related genes was largely unaffected by SARS-CoV-2 infection, cells infected with H1N1 showed significantly altered expression of all six genes, with ACE2, FURIN, NRP1 and NRP2 being significantly upregulated compared to uninfected controls at 9 dpi (Fig. 6a). We found FURIN to be of special interest,




Fig. 5 Protein production by epithelial cells in response to SARS-CoV-2 infection was minimal compared to H1N1. a, b Concentrations of indicated proteins in the basal media from epithelial cells infected with SARS-CoV-2 or H1N1. Dotted lines denote lower limit of detection. Asterisks denote statistically significant change from uninfected controls. Statistics: Mann–Whitney test. *p < 0.05; **p < 0.01. c Spearman correlation between viral titres and protein concentrations in basal media of cells paediatric and adult cells infected with SARS-CoV-2 or H1N1. Correlation coefficients and p values are shown for each treatment individually (purple, SARS-CoV-2; teal, H1N1).

as its expression was induced early following H1N1 infection and remained consistently elevated through the experiment. *FURIN* levels did not correlate with viral titres (Fig. 6b), suggesting that expression of this gene is likely controlled by mechanisms distinct from the antiviral and pro-inflammatory response. Similarly, *NRP1* expression levels were unchanged at 3 dpi but increased significantly and continuously from 5 dpi. Together, these data indicate that H1N1 infection resulted in sustained upregulation of SARS-CoV-2 entry-related genes in bronchial epithelial cells even after viral titres decreased. If similar events took place in vivo, they may result in an increased risk of SARS-CoV-2 infection in patients recently recovering from influenza.

DISCUSSION

There are growing efforts to understand why children typically develop less severe COVID-19 disease than adults, which is in contrast to findings from other respiratory viruses that have resulted in pandemics, such as H1N1. The mechanisms underlying these discrepancies in COVID-19 severity remain poorly understood. Here, we hypothesised that intrinsic differences in the responses of healthy paediatric and adult bronchial epithelial cells to infection with SARS-CoV-2 could explain the differences observed according to age. In order to understand whether susceptibility to infection and immune responses were specific for

SARS-CoV-2, we compared it to H1N1. Our characterisation of viral replication and epithelial immune responses following SARS-CoV-2 infection of differentiated bronchial epithelial cells from healthy children and adults showed indistinguishable infection susceptibility and immune responses between paediatric and adult cells. However, we acknowledge that a larger sample size may have revealed age-related differences. SARS-CoV-2 infection induced a robust transcriptional interferon response, which was delayed compared to H1N1 infection, in line with slower viral replication of SARS-CoV-2. Protein production and repair responses were also much lower in SARS-CoV-2- compared to H1N1-infected cells, and only H1N1 infection resulted in changes to the morphology and composition of the epithelial layer.

Mounting evidence cements the central role of type I IFNs in the generation of effective responses to SARS-CoV-2 infection, including observations of higher prevalence of loss-of-function mutations or auto-antibodies interfering with type I IFN signalling in patients with life-threatening COVID-19^{24,25}. The benefit of interferon signalling has also been demonstrated in primary airway epithelial cells in vitro, where the application of either type I and III IFNs before or early after infection with SARS-CoV-2 was shown to result in reduced viral burden in both nasal and bronchial epithelial cells^{35,37,38}. A recent study comparing the upper airway transcriptome of healthy uninfected and SARS-CoV-2-infected children and adults using single-cell RNA sequencing




Fig. 6 Infection of bronchial epithelial cells with H1N1 resulted in prolonged upregulation of SARS-CoV-2 entry-related genes independent of viral titres. a Gene expression analysis by qPCR of infected bronchial epithelial cells. Data shown as median \pm confidence interval of paediatric (n = 5-6) and adult (n = 4) donors pooled together. Asterisks denote statistically significant change from uninfected control. Statistics: Mann–Whitney test. *p < 0.05; ***p < 0.01; ****p < 0.001; ****p < 0.001. b Spearman correlation between viral titres and gene expression of indicated genes in cells infected with SARS-CoV-2 or H1N1. Correlation coefficients and p values are shown for each treatment individually (purple, SARS-CoV-2; teal, H1N1).

(scRNA-seq) of nasal swabs reported higher expression of IFIH1 and DDX58 in epithelial cells from children, both at baseline and during the early phase of SARS-CoV-2 infection²⁰. IFIH1 and DDX58 encode MDA5 and RIG-I, respectively, two PRRs important in the induction of interferon signalling in response to infection with viruses, of which MDA5 was specifically shown to contribute to sensing of SARS-CoV-2^{35,39}. As such, a higher expression of the relevant PRRs needed for the induction of IFN signalling might potentially result in faster and stronger antiviral signalling upon infection. In line with this, a study comparing nasopharyngeal swabs from 12 children and 27 adults admitted to the emergency department with SARS-CoV-2 infection found increased levels of interferons, ISGs and pro-inflammatory cytokines in nasal fluids from children compared to adults. This heightened immune response signature aligned with better clinical outcomes²¹, suggesting children may indeed be more poised to mount an inflammatory response to SARS-CoV-2 than adults.

When we compared the expression of IFIH1 and DDX58 between bronchial epithelial cell cultures collected from healthy children and adults and cultured at air-liquid interface, we did not observe any differences in PRR expression or the ability of the cells to mount an antiviral interferon response to infection with SARS-CoV-2. We cannot exclude that a comparison of nasal rather than bronchial epithelial cells or an increase in sample size would have revealed differences between groups, and potentially even in the ability to control SARS-CoV-2 replication. However, it is more likely that the increased PRR expression levels in children are not an intrinsic feature of paediatric airway epithelia, but rather a result of environmental influences. An increased antiviral interferon signature, including increased expression of PRRs, could be the result of recent respiratory virus infections, which are more common in children compared to adults⁴¹. The effects of infection history are not limited to the airway epithelium; a study has reported the existence of SARS-CoV-2 spike glycoprotein (S)-binding antibodies

in the serum of individuals not previously exposed to the virus or the vaccine⁴². These pre-existing antibodies were most commonly found in children and adolescents and are thought to be cross-reactive immunological memory originally mounted in response to other seasonally circulating human coronaviruses, which are more prevalent in children compared to adults^{43,44}.

Allowing for a relatively modest sample size, our preliminary findings suggest that disparate disease severity of COVID-19 between children and adults may not be the result of cell-intrinsic differences between paediatric and adult airway epithelia. This interpretation warrants further investigation in future studies that should aim to increase the sample size and include epithelial cells from a wider age range of subjects. Even so, it is unlikely that infection history alone is the deciding factor for disease severity. It is thus important to also consider the contribution of other anatomical sites and cell types. While our model is ideally suited for the detailed characterisation of the normal airway epithelial response to SARS-CoV-2 infection, it is unable to reflect the progression of SARS-CoV-2 to the alveoli, a process associated with the development of severe disease²⁷. Another limitation of the present study is the inability to demonstrate how airway epithelial cells interact with other structural and immune cells and how this may shape the response to infection, including viral clearance. The use of scRNA-seq in samples from individuals infected with SARS-CoV-2 has provided some insights into these interactions in the context of diverging COVID-19 susceptibility and severity between children and adults^{20,45}. In addition to differences in epithelial expression of pattern recognition receptors, as discussed above, these studies demonstrated augmented frequencies of diverse lymphocyte populations, such as innate lymphoid cells and various T cell subsets, in children. Ultimately, it is likely that many factors, coupled with their interaction with each other, influence the disparate disease severity in individuals infected with SARS-CoV-2.

A stark finding of our study was the pronounced difference between infection with SARS-CoV-2 versus H1N1. SARS-CoV-2 showed much lower release of infectious particles compared to H1N1, suggesting a diminished ability to replicate in airway epithelia. This may explain the longer incubation period of around 6 days for SARS-CoV-2⁴⁶ compared to the much shorter incubation period of 1–4 days for H1N1⁴⁷ in infected individuals. Interestingly, we found no evidence of damage or overt pro-inflammatory responses after SARS-CoV-2 infection, both of which were evident in H1N1-infected cells. This is surprising considering both viruses have similar spectra of disease severity and case fatality rates are estimated to be even higher for COVID-19 compared to influenza⁴⁸. This suggests that, in contrast to H1N1, the epithelial response to SARS-CoV-2 may be less consequential to disease severity

Early studies of SARS-CoV-2 infection in ALI cultures of bronchial epithelial cells reported an inability of the cells to mount an interferon response to the virus^{36,37}. In contrast, various other reports have more recently demonstrated induction of interferon signalling upon SARS-CoV-2 infection in primary nasal, tracheal and bronchial epithelial cells^{34,35,38,39,49,50}. Of note, interferon and ISG induction was primarily reported during later stages of the infection (around 2-4 dpi) and was delayed and of lower magnitude when compared to infection with Influenza A H1N1³⁸ or H3N2³⁴, a finding which is replicated in our data. This delay in the onset of the interferon response was hypothesised to result from the ability of SARS-CoV-2 to subvert early interferon induction. Several viral evasion strategies of SARS-CoV-2 have been brought to light. These include the use of double-membrane vesicles for viral RNA synthesis⁵¹ and the ability of non-structural proteins and other viral proteins to inhibit interferon induction and signalling^{52,53} as well as interference with protein translation^{54–57}. However, our data indicate a strong correlation between levels of infectious viral particles released into the apical wash and gene expression of *IFNB1*, *IFNL1* and several ISGs following infection with either SARS-CoV-2 or H1N1, suggesting that reduced ability of SARS-CoV-2 to replicate in bronchial epithelial cells, rather than its evasion strategies, is the major driver for the delayed interferon response at transcriptional level. Nevertheless, the minimal protein release from SARS-CoV-2-infected cells, both apically and basolaterally, did not match the robust interferon induction elicited at transcriptional level, suggesting that viral interference with protein translation may have occurred.

Lastly, we observed that infection with H1N1 resulted in prolonged upregulation of the SARS-CoV-2 entry-related genes FURIN and NRP1 that was not linked to viral titres. Both furin and neuropilin 1 have been shown to potentiate SARS-CoV-2 infectivity^{11,13,14}. It may be that an increased expression of these proteases renders individuals recovering from flu more susceptible to SARS-CoV-2 infection. Co-infection experiments in primary airway epithelial cells, while beyond the scope of the present study, will be instrumental in supporting this hypothesis. In their absence, however, others have shown influenza A pre-infection to increase the infectivity of SARS-CoV-2 in vitro⁵⁸ and mice infected with influenza and subsequently SARS-CoV-2 displayed enhanced disease susceptibility and pathology compared to those infected with SARS-CoV-2 alone 58,59. Importantly, a study evaluating 19,256 individuals tested for both influenza and SARS-CoV-2 in England identified a greater risk of death in patients with co-infection compared to those infected with either virus alone⁶⁰. These findings underscore the absolute need for public policy to urge immunisation against influenza as well as COVID-19.

Overall, we demonstrated that intrinsic differences in bronchial epithelial cells from children and adults did not explain the discrepancies in COVID-19 disease susceptibility and severity seen between those groups. However, when comparing two viruses that have both resulted in pandemics, there was a stark difference in epithelial damage and immune responses. In addition to a previously described delay in induction of interferon signalling, which we were able to link to delayed replication, SARS-CoV-2 caused no damage to the epithelial layer and displayed an overall diminished capacity to evoke epithelial immune responses at both mRNA and protein level. In contrast, H1N1 infection resulted in rapid viral replication, robust epithelial damage, altered morphology of the cell layer and markedly greater immune responses.

METHODS

Patient recruitment and sampling

Ethical approval for sample collection was granted by the Research Ethics Committee (17/LO/0013 and 15/SC/0101) and all patients or parents provided informed written consent.

Children aged 2–5 with no history of wheezing or other respiratory pathology (n=6) (Table 1) were recruited as part of the Breathing Together study as previously described⁶¹. Bronchial epithelial cells were collected by blind endobronchial brushing from children undergoing anaesthesia for an elective surgical procedure requiring clinically indicated intubation, and nasal epithelial cells were collected from the same donors as previously described⁶¹. Healthy adults (n=4) (Table 1) were recruited for bronchoscopies, during which bronchial brushes were taken from the right mainstem bronchus. Brushes were collected in DMEM media containing penicillin (100 U/ml) and streptomycin (100 µg/ml; all Gibco). Cells were detached by agitation and then expanded for two passages in Airway Epithelial Cell Growth Medium (Promocell) containing 100 µg/ml Primocin (InvivoGen) in flasks coated with 30 µg/ml (bronchial) or 100 µg/ml (nasal epithelial cells) bovine Type I Collagen Solution (BioMatrix) before cryopreservation.

Air-liquid interface culture of epithelial cells

Cryopreserved cells were expanded in Airway Epithelial Cell Growth Medium containing penicillin and streptomycin before seeding onto collagen-coated (30 μ g/ml type I collagen) 24-well Transwell inserts (polyethylene terephthalate membrane with 0.4 μ m pores; Corning) at a density of 3 \times 10⁴ per insert. A 1:1 mix of Airway Epithelial Growth Medium (without the Triiodo-L-

Table 2. TagMan[™] assays used for gene expression analysis.

Gene	Assay ID	Gene (cont.)	Assay ID (cont.)
ACE2 (full-length isoform)	Hs00222343_m1	IFIT1	Hs00356631_g1
AREG	Hs00950669_m1	IFNB1	Hs01077958_s1
ATP5B (housekeeping)	Hs00969569_m1	IFNL1	Hs00601677_g1
BTC	Hs01101204_m1	IL6	Hs00174131_m1
CTSL	Hs00964650_m1	ISG15	Hs01921425_s1
CXCL10	Hs01124252_g1	KRT5	Hs00361185_m1
CXCL8	Hs00174103_m1	MUC5AC	Hs01365616_m1
DDX58	Hs01061436_m1	MUC5B	Hs00861595_m1
EGF	Hs01099990_m1	NRP1	Hs00826128_m1
EGFR	Hs01076090_m1	NRP2	Hs00187290_m1
EPGN	Hs02385424_m1	TGFA	Hs00608187_m1
EREG	Hs00914313_m1	TJP1	Hs01551861_m1
FOXJ1	Hs00230964_m1	TMPRSS2	Hs01122322_m1
FURIN	Hs00965485_g1	TNF	Hs00174128_m1
HBEGF	Hs00181813_m1	YWHAZ (housekeeping)	Hs01122445_g1
IFIH1	Hs00223420_m1		

Table 3. Antibodies used for immunofluorescence staining.

Primary antibodies			
Antibody (clone)	Conjugate	Supplier (catalogue #)	Concentration
ACE-2	-	R&D Systems (AF933)	4.0 μg/ml
Mucin 5AC (EPR16904)	AF555	abcam (ab218714)	5.0 μg/ml
Cytokeratin 5 (EP1601Y)	AF647	abcam (ab193895)	2.5 μg/ml
Goat IgG, polyclonal (isotype)	-	abcam (ab37373)	4.0 μg/ml
SARS Nucleocapsid protein	-	Novus Bio (NB100-56576)	10.0 µg/ml
Alpha Tubulin (6-11B-1)	-	abcam (ab24610)	10.0 μg/ml
Rabbit IgG, Control Antibody	_	Vector Labs (I-1000-5)	10.0 μg/ml
Secondary antibodies			
Antibody	Conjugate	Supplier (catalogue #)	Concentration
Donkey anti-mouse IgG	AF488	Invitrogen (A-21202)	10.0 µg/ml
Donkey anti-rabbit IgG	AF594	Invitrogen (A-21207)	10.0 µg/ml
Donkey anti-goat IgG	AF488	Invitrogen (A-11055)	10.0 μg/ml

thyronine supplement) containing penicillin and streptomycin and DMEM (high glucose, GlutaMAX $^{\text{TM}}$, pyruvate; Gibco) containing penicillin and streptomycin, 25 mM HEPES (Gibco) and 1.5 μ g/ml BSA (Sigma) was used for maintenance of the cells during seeding and submerged phase of the culture, with 200 μ l and 500 μ l of medium in the apical and basal compartment, respectively. Medium was changed every 2–4 days.

Upon confluency, apical medium was removed, and the basal medium was replaced with PneumaCult™-ALI Medium containing 0.0004% Heparin, 0.48 µg/ml hydrocortisone (all Stemcell) and penicillin and streptomycin. Basal medium was refreshed every 2–4 days until cells were fully differentiated (4–9 weeks) and where necessary, mucus was removed by addition of 100 µl PBS to the apical compartment for 5 min before removal.

At least 48 h before infection, hydrocortisone was withdrawn from the media and cells were cultured without hydrocortisone for the entirety of the experiment. Apical washes and basal media were collected 24 hours after infection and then every 48 h. For apical washes, 200 μl of PBS were added to the apical compartment and collected after 10 min of incubation at room temperature.

Viral stocks, infection, and determination of viral titres

All work involving the use of live SARS-CoV-2 or H1N1 was carried out in the Containment Level 3 (CL3) or Containment Level 2 (CL2) laboratories

(St. Mary's, Imperial College London), respectively. Stocks of SARS-CoV-2 (SARS-CoV-2/England/IC19/2020) and Influenza H1N1 (A/England/195/2009) were propagated in Vero-E6 or MDCK cells, respectively.

Prior to infection, the apical compartment was washed once with PBS and the basal media was replaced. A cell density of 2.5×10^5 cells per insert was assumed. 2.5×10^3 PFU SARS-CoV-2 (MOI 0.01), 2.5×10^2 PFU H1N1 (MOI 0.001) or serum-free DMEM were added to the apical compartment in a total volume of 100 μ l and cells were incubated for 1 hr at 37 °C/5% CO $_2$ before apical liquid was removed and cells were returned to the incubator.

Viral titres of SARS-CoV-2 and H1N1 in apical washes were determined using plaque assays in Vero-E6 or MDCK cells, respectively.

Protein mediator analysis

All samples were irradiated prior to analysis to allow work to be conducted outside of CL2 or CL3 facilities. Levels of IFN- β , IFN- λ 1/3, IL-6 and IL-8 were measured in basal media or apical washes from at least three inserts per condition using DuoSet ELISA kits (R&D Systems) according to manufacturer's recommendation. Levels of 105 cytokines were measured in pooled basal media from four paediatric or adult donors, respectively, using the Proteome Profiler Human XL Cytokine Array Kit (R&D Systems) according to manufacturer's recommendation.

Gene expression analysis

Total RNA was extracted from two Transwell inserts per condition using the Maxwell® RSC simplyRNA Blood kit on the Maxwell® RSC instrument (both Promega) and transcribed into cDNA using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). Expression of genes of interest relative to the expression of two housekeeping genes (*ATPSB*, *YWHAZ*) was determined using TaqMan™ Fast Advanced reagents on a ViiA 7 Real-Time PCR system (both Applied Biosystems). TaqMan™ assay IDs are listed in Table 2.

Histology and immunofluorescence staining

Whole inserts were fixed in 4% (w/v) paraformaldehyde in PBS for 20 min at room temperature. Membranes were excised from inserts and embedded in 4% low melting point agarose (Thermo Scientific) prior to paraffin embedding and sectioning at 4 µm thickness. Paraffin embedding, sectioning and haematoxylin and eosin (H&E) staining were performed by Lorraine Lawrence of the Histology facility at Imperial College London. For immunofluorescence staining, slides were subjected to heat-induced antigen retrieval in 1 mM EDTA, pH 8.0 prior to blocking in PBS containing 10% donkey serum and 0.1% Tween 20 and incubation with antibodies in 1% BSA in PBS at the concentrations indicated in Table 3. In some instances, DAPI (Sigma-Aldrich) was included as a counterstain for nuclei. Images were acquired using the Aperio VERSA slide scanner (Leica) at a maximum magnification of x40. Epithelial height was measured in H&Estained sections using ImageScope Software (Leica). Fluorescence images were adjusted for contrast and gamma in ImageScope software before export. Fiji software⁶² was used to rotate and crop images, apply pseudocolours and add scale bars. For visualisation of overlap between stains, segmentation was applied on inverted single-channel images using the PHANTAST⁶³ plug-in for Fiji and overlapping areas between different colours were identified using the Image Calculator function.

Data analysis and statistics

All data processing, analysis and plotting was conducted in R Studio. For statistical analyses, the R stats package was used. When comparing between two groups, exact p values were computed using a two-sided Mann–Whitney test and p values < 0.05 were considered statistically significant. For correlations, exact p values and rank correlation coefficients (rho) were calculated using the Spearman method. Principal component analysis was conducted on centred and scaled data and the first two principal components were plotted. Data was visualised using the ggplot2 package.

REFERENCES

- 1. Jhung, M. A. et al. Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. *Clin. Infect. Dis.* **52**, S13–S26 (2011).
- Li, J. et al. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J. Med Virol. 93, 1449–1458 (2021).
- Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. *JAMA* 323, 1239–1242 (2020).
- O'Driscoll, M. et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 590, 140–145 (2021).
- Lu, X. et al. SARS-CoV-2 infection in children. N. Engl. J. Med 382, 1663–1665 (2020).
- Cui, X. et al. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). J. Med Virol. 93, 1057–1069 (2021).
- Goldstein, E., Lipsitch, M. & Cevik, M. On the effect of age on the transmission of SARS-CoV-2 in households, schools, and the community. J. Infect. Dis. 223, 362–369 (2021).
- Ladhani, S. N. et al. COVID-19 in children: analysis of the first pandemic peak in England. Arch. Dis. Child 105, 1180–1185 (2020).
- Zhu, Y. et al. A meta-analysis on the role of children in severe acute respiratory syndrome coronavirus 2 in household transmission clusters. Clin. Infect. Dis. 72, e1146–e1153 (2021).
- Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280 e278 (2020).
- Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc. Natl Acad. Sci. USA 117, 11727–11734 (2020).
- Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620 (2020).

- Cantuti-Castelvetri, L. et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370, 856–860 (2020).
- Daly, J. L. et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science 370, 861–865 (2020).
- 15. Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. *Cell* **182**, 429–446 e414 (2020).
- Saheb Sharif-Askari, N. et al. Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD. Mol. Ther. Methods Clin. Dev. 18, 1–6 (2020).
- Bunyavanich, S., Do, A. & Vicencio, A. Nasal gene expression of angiotensinconverting enzyme 2 in children and adults. JAMA 323, 2427–2429 (2020).
- Ortiz, M. E. et al. Heterogeneous expression of the SARS-Coronavirus-2 receptor ACE2 in the human respiratory tract. EBioMedicine 60, 102976 (2020).
- Wark, P. A. B. et al. ACE2 expression is elevated in airway epithelial cells from older and male healthy individuals but reduced in asthma. *Respirology* 26, 442–451 (2021).
- Loske J. et al. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nat Biotechnol 3, 319–324 (2021).
- Pierce C. A. et al. Natural mucosal barriers and COVID-19 in children. JCI Insight 6, e148694 (2021).
- Vareille, M., Kieninger, E., Edwards, M. R. & Regamey, N. The airway epithelium: soldier in the fight against respiratory viruses. *Clin. Microbiol Rev.* 24, 210–229 (2011).
- Ciancanelli, M. J. et al. Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science 348, 448–453 (2015).
- Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with lifethreatening COVID-19. Science 370, eabd4570 (2020).
- Bastard, P. et al. Autoantibodies against type I IFNs in patients with lifethreatening COVID-19. Science 370, eabd4585 (2020).
- Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718–724 (2020).
- Mason R. J. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J 55, 2000607 (2020).
- Sungnak, W. et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 26, 681-687 (2020).
- Berube, K., Prytherch, Z., Job, C. & Hughes, T. Human primary bronchial lung cell constructs: the new respiratory models. *Toxicology* 278, 311–318 (2010).
- Ostrowski, L. E., Stewart, D. & Hazucha, M. Interferon gamma stimulates accumulation of gas phase nitric oxide in differentiated cultures of normal and cystic fibrosis airway epithelial cells. *Lung* 190, 563–571 (2012).
- Comer, D. M., Kidney, J. C., Ennis, M. & Elborn, J. S. Airway epithelial cell apoptosis and inflammation in COPD, smokers and nonsmokers. *Eur. Respir. J.* 41, 1058–1067 (2013).
- 32. Chason, K. D. et al. Age-associated changes in the respiratory epithelial response to influenza infection. *J. Gerontol. A Biol. Sci. Med Sci.* **73**, 1643–1650 (2018).
- 33. Hao, S. et al. Long-term modeling of SARS-CoV-2 infection of in vitro cultured polarized human airway epithelium. *mBio* 11, e02852–20 (2020).
- 34. Gamage, A. M. et al. Infection of human nasal epithelial cells with SARS-CoV-2 and a 382-nt deletion isolate lacking ORF8 reveals similar viral kinetics and host transcriptional profiles. PLoS Pathog. 16, e1009130 (2020).
- Rebendenne, A. et al. SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells. J Virol 95, e02415–20 (2021).
- Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036–1045 e1039 (2020).
- Vanderheiden, A. et al. Type I and Type III interferons restrict SARS-CoV-2 infection of human airway epithelial cultures. J Virol 94, e00985–20 (2020).
- Hatton, C. F. et al. Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2. Nat. Commun. 12, 7092 (2021).
- Yin, X. et al. MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Rep. 34, 108628 (2021).
- Burgel, P. R. & Nadel, J. A. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. *Thorax* 59, 992–996 (2004).
- 41. Monto, A. S. & Ullman, B. M. Acute respiratory illness in an American community: the Tecumseh study. *JAMA* **227**, 164–169 (1974).
- 42. Ng, K. W. et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science* **370**, 1339–1343 (2020).
- Dijkman, R. et al. Human coronavirus NL63 and 229E seroconversion in children. J. Clin. Microbiol 46, 2368–2373 (2008).
- Friedman, N. et al. Human coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU1. Viruses 10, 515 (2018).
- Yoshida, M. et al. Local and systemic responses to SARS-CoV-2 infection in children and adults. Nature 602, 321–327 (2022).

- Elias, C., Sekri, A., Leblanc, P., Cucherat, M. & Vanhems, P. The incubation period of COVID-19: A meta-analysis. Int J. Infect. Dis. 104, 708–710 (2021).
- Park, J. E. & Ryu, Y. Transmissibility and severity of influenza virus by subtype. Infect. Genet Evol. 65, 288–292 (2018).
- da Costa, V. G., Saivish, M. V., Santos, D. E. R., de Lima Silva, R. F. & Moreli, M. L. Comparative epidemiology between the 2009 H1N1 influenza and COVID-19 pandemics. J. Infect. Public Health 13, 1797–1804 (2020).
- Ravindra, N. G. et al. Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell state changes. *PLoS Biol.* 19, e3001143 (2021).
- Cheemarla, N. R. et al. Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics. J Exp Med 218, e20210583 (2021).
- 51. Wolff, G. et al. A molecular pore spans the double membrane of the coronavirus replication organelle. *Science* **369**, 1395–1398 (2020).
- Kumar, A. et al. SARS-CoV-2 nonstructural protein 1 inhibits the interferon response by causing depletion of key host signaling factors. J. Virol. 95, e0026621 (2021)
- 53. Lei, X. et al. Activation and evasion of type I interferon responses by SARS-CoV-2.
- Schubert, K. et al. SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation. Nat. Struct. Mol. Biol. 27, 959–966 (2020).
- Thoms, M. et al. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science 369, 1249–1255 (2020).
- Finkel, Y. et al. SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis. *Nature* 594, 240–245 (2021).
- 57. Hsu J. C., Laurent-Rolle M., Pawlak J. B., Wilen C. B. & Cresswell P. Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein. *Proc Natl Acad Sci USA* **118**, e2101161118 (2021).
- 58. Bai, L. et al. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. *Cell Res* **31**, 395–403 (2021).
- Achdout, H. et al. Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by influenza immunity but not SARS-CoV-2 immunity. *Nat. Commun.* 12. 5819 (2021).
- Stowe, J. et al. Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design. *Int J. Epidemiol.* 50, 1124–1133 (2021)
- 61. Turner, S. et al. Pulmonary epithelial barrier and immunological functions at birth and in early life - key determinants of the development of asthma? A description of the protocol for the Breathing Together study. Wellcome Open Res 3, 60 (2018).
- 62. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 (2012).
- Jaccard, N. et al. Automated method for the rapid and precise estimation of adherent cell culture characteristics from phase contrast microscopy images. *Biotechnol. Bioeng.* 111, 504–517 (2014).

ACKNOWLEDGEMENTS

We would like to thank Dr James Harker and Dr Franz Puttur for their guidance in planning this study, as well as for their feedback on the manuscript. This study was

supported by the Imperial College COVID-19 Response Fund to C.M.L., S.S. and W.S.B., a Wellcome Trust Strategic Award (108818/15/Z) to the Breathing Together Consortium, a Wellcome Trust Senior Research Fellowship in Basic Biomedical Sciences (107059/Z/15/Z) to C.M.L. and a British Lung Foundation PhD studentship to H.S.

AUTHOR CONTRIBUTIONS

H.S. performed and analysed experiments. L.B., R.F. and M.L.G. performed experiments and helped with study design. H.S., W.S.B., S.S. and C.M.L. were responsible for the overall study design. K.L.B., R.J.H., P.L.M. and the BT Consortium recruited donors. H.S. wrote the manuscript and S.S. and C.M.L. contributed to the editing process. All authors read and approved the manuscript.

COMPETING INTERESTS

C.M.L. and B.M. (of the Breathing Together consortium) are members of the editorial board for Mucosal Immunology. All other authors declare no conflict of interest.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41385-022-00545-4.

Correspondence and requests for materials should be addressed to Sejal Saglani or Clare M. Lloyd.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third particle material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="https://creative.commons.com/https://creative.commons.com/https://creative.commons.com/https://creative.commons.com/https://creative.commons.com/https://creative.commons.com/https://creative.commons.com/https://creative.commons.com/https://creative.commons.com/https://creative.commons.com/https://creative.commons.com/https://creative.commons.com/https://creative.commons.com/https://creative.commons.com/https://creative.commons.com/https://creative

© The Author(s) 2022

creativecommons.org/licenses/by/4.0/.

BREATHING TOGETHER CONSORTIUM

Steve Turner⁵, Adnan Custovic⁶, Peter Ghazal⁷, Jonathan Grigg⁸, Mindy Gore⁶, Raquel Granell⁹, Clare M. Lloyd on the Lloyd state of the Steve Turner⁵, Adnan Custovic⁶, Peter Ghazal⁷, Jonathan Grigg⁸, Mindy Gore⁶, Raquel Granell⁹, Clare M. Lloyd on the Ll

⁵Child Health, University of Aberdeen, Aberdeen AB25 2ZG, UK. ⁶Department of Paediatrics, Imperial College and Royal Brompton Hospital, London SW3 6NP, UK. ⁷Division of Infection and Pathway Medicine, Deanery of Biomedical Sciences, University of Edinburgh Medical School, Edinburgh EH16 4TJ, UK. ⁸Centre for Child Health, Blizard Institute, Queen Mary University of London, London E1 2AT, UK. ⁹MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2BN, UK. ¹⁰Department of Immunology and Pathology, Monash University, Melbourne, VIC 3004, Australia. ¹¹Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast BT9 7BL, UK. ¹²Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK. ¹³NIHR Southampton Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK. ¹⁴The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Newport, Isle of Wight, Trust PO30 5TG, UK. ¹⁵Child Life and Health, Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK.